Purple sweet potato color suppresses lipopolysaccharide-induced acute inflammatory response in mouse brain.
The neuroprotective effects of purple sweet potato color (PSPC), which is natural anthocyanin food colors, have been investigated in mice treated with lipopolysaccharide (LPS). In behavioral tests, oral administration of PSPC could significantly reverse the impairment of motor and exploration behavior induced by LPS in the open field tasks, and also improve learning and memory ability in step-through tests. Western blot analysis indicated that PSPC significantly suppressed LPS-induced cyclooxygenase-2 (COX-2) and inducible nitric oxide synthases (iNOS) expression in mouse brain. PSPC also markedly decreased the overproduction of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) in LPS-stimulated mouse brain. Mechanistically, PSPC strongly inhibited LPS-induced phosphorylated extracellular signal-regulated kinase (ERK) and phosphorylated c-Jun N-terminal kinase (JNK) expression and nuclear factor kappa B (NF-kappaB) activation. Taken together, these data suggest that PSPC may be useful for mitigating inflammatory brain diseases by the inhibition of proinflammatory molecule production, at least in part, through blocking ERK, JNK and NF-kappaB signaling.
Wang
Yong-Jian
YJ
Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Xuzhou Normal University, No 101 Shanghai Road, Xuzhou 221116, Jiangsu Province, PR China.
Zheng
Yuan-Lin
YL
Lu
Jun
J
Chen
Guo-Qing
GQ
Wang
Xiao-Hui
XH
Feng
Jie
J
Ruan
Jie
J
Sun
Xiao
X
Li
Chun-Xiang
CX
Sun
Qiu-Ju
QJ
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D004660:Encephalitis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000633:toxicity; D027723:Ipomoea batatas / Q000737:chemistry*; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000633:toxicity; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000502:physiology; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009069:Movement Disorders / Q000188:drug therapy / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D052246:Cyclooxygenase 2 Inhibitors; D016207:Cytokines; D004365:Drugs, Chinese Herbal; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D018696:Neuroprotective Agents; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse